

Papers related to the NBCSP, published in peer reviewed journals by June 26th 2017

1. Ottestad PM (1996)
IT solutions in a centrally organised mammography screening in Norway. Medical Informatics Europe
2. Wang H, Thoresen S, Tretli S (1998)
Breast cancer in Norway 1970-1993: a population-based study on incidence, mortality and survival. Br J Cancer.
3. Thoresen S (1999)
Mammography screening of women aged 40 plus--how long must the Norwegian women wait this time?] Tidsskr Nor Laegeforen. Norwegian.
4. Kåresen R, Bo JK, Hustveit S et al (1999)
Cost-effectiveness of mammography screening in Norway] Tidsskr Nor Laegeforen. Norwegian.
5. Thoresen S (2000)
Different motives behind criticism of mass screening for cancer of the breast and cervix uteri] Tidsskr Nor Laegeforen. Norwegian.
6. Wang H, Jepsen P, Kåresen R et al (2000)
Ductal Carcinoma In Situ of the breast. A review of Diagnosis, treatment and outcome in a hospital based Norwegian series. Acta Oncologica
7. Iversen BF, Eriksen L (2000)
[Mammography screening in Rogaland--the first round] Tidsskr Nor Laegeforen. Norwegian.
8. Wang H, Hofvind S, Thoresen S (2000)
[A pilot project with mammography--results from the first screening round] Tidsskr Nor Laegeforen. 2000 Nov 10;120(27):3237-40. Norwegian.
9. Thoresen S (2001)
Mammography screening saves life] Tidsskr Nor Laegeforen. Norwegian.
10. Wang H, Kåresen R, Hervik A et al (2001)
Mammography screening in Norway: results from the first screening round in four counties and cost-effectiveness of a modeled nationwide screening. Cancer Causes Control.
11. Hofvind S, Thoresen S (2001)
Physical activity and breast cancer] Tidsskr Nor Laegeforen. Norwegian
12. Wang H, Bjustam H, Bjørndal H et al (2001)
Interval cancers in the Norwegian breast cancer screening program: frequency, characteristics and use of HRT. Int J Cancer.
13. Ekeberg O, Skjauff H, Karesen R. (2001)
Screening for breast cancer is associated with a low degree of psychological distress. Breast
14. Klabunde CN, Sancho-Garnier H, Broeders M et al (2001)
Quality assurance for screening mammography data collection systems in 22 countries. Int J Technol Assess Health Care.
15. Wang H, Hofvind S, Tretli S et al (2002)
Does organized mammographic screening reduce breast cancer mortality? The Cancer Registry's view on the current debate] Tidsskr Nor Laegeforen. Norwegian.
16. Klabunde CN, Sancho-Garnier H, Taplin S et al (2002)
Quality assurance in follow-up and initial treatment for screening mammography programs in 22 countries. Int J Qual Health Care.
17. Sauer T, Young K, Thoresen S (2002)
Fine needle aspiration cytology in the work-up of mammographic and ultrasonographic findings in breast cancer screening: an attempt at differentiating in situ and invasive carcinoma. Cytopathology.
18. Hofvind S, Wang H, Thoresen S (2003)
The Norwegian Breast Cancer Screening Program: re-attendance related to the women's experiences, intentions and previous screening result. Cancer Causes Control.

19. Hofvind S, Wang H, Thoresen S (2003)
[Introduction and evaluation of screening] Tidsskr Nor Laegeforen. Norwegian.
20. Skaane P, Young K, Skjennald A (2003)
Population-based mammography screening: comparison of screen-film and full-field digital mammography with soft-copy reading--Oslo I study. Radiology.
21. Sauer T, Myrvold K, Lomo J et al (2003)
Fine-needle aspiration cytology in nonpalpable mammographic abnormalities in breast cancer screening: results from the breast cancer screening programme in Oslo 1996-2001. Breast.
22. Obenaauer S, Hermann KP, Marten K et al (2003)
Soft copy versus hard copy reading in digital mammography. J Digit Imaging.
23. Hofvind S, Wang H, Thoresen S (2004)
Do the results of the process indicators in the Norwegian Breast Cancer Screening Program predict future mortality reduction from breast cancer? Acta Oncol.
24. Skaane P, Skjennald A (2004)
Screen-film mammography versus full-field digital mammography with soft-copy reading: randomized trial in a population-based screening program--the Oslo II Study. Radiology.
25. Hofvind S, Thoresen S, Tretli S (2004)
The cumulative risk of a false-positive recall in the Norwegian Breast Cancer Screening Program. Cancer.
26. Langmark F and Thoresen S (2004)
Overdiagnosis and mammography screening] Tidsskr Nor Laegeforen. Author reply. Norwegian
27. Skaane P, Skjennald A, Young K et al (2005)
Follow-up and final results of the Oslo I Study comparing screen-film mammography and full-field digital mammography with soft-copy reading. Acta Radiol.
28. Skaane P, Balleyguier C, Diekmann F et al (2005)
Breast lesion detection and classification: comparison of screen-film mammography and full-field digital mammography with soft-copy reading--observer performance study. Radiology
29. Collett K, Stephansen IM, Eide J et al (2005)
A basal epithelial phenotype is more frequent in interval breast cancers compared with screen detected tumors. Cancer Epidemiol Biomarkers Prev.
30. Skaane P (2004)
CAD--the future blessing for radiology? Acta Radiol.
31. Skaane P (2004)
To believe or not to believe: looking into the unbelievable. Acta Radiol.
32. Hofvind S, Skaane P, Vitak B (2005)
Influence of review design on percentages of missed interval breast cancers: retrospective study of interval cancers in a population-based screening program. Radiology.
33. Weedon-Fekjaer H, Vatten L, Aalen O et al (2005)
Estimating mean sojourn time and screening test sensitivity in breast cancer mammography screening: new results. J Med SScreen
34. Møller B, Weedon-Fekjaer H, Hakulinen T, Tryggvadóttir L, Storm HH, Talbäck M, Haldorsen T. (2005). The influence of mammographic screening on national trends in breast cancer incidence. Eur J Cancer Prev.
35. Gram IT, Bremnes Y, Ursin G, Maskarinec G, Bjurstam N, Lund E (2005)
Percentage density, Wolfe's and Tabár's mammographic patterns: agreement and association with risk factors for breast cancer. Breast Cancer Res.
36. Hofvind S, Møller B, Thoresen S et al (2006)
Use of hormone therapy and risk of breast cancer detected at screening and between mammographic screens. Int J Cancer
37. Skaane P, Niklason L (2006)
Receiver operating characteristic analysis: a proper measurement for performance in breast cancer screening? AJR Am J Roentgenol. Author reply.

38. Hofvind S, Bjurstam N, Sørum R et al (2006)
Number and characteristics of breast cancer cases diagnosed in four periods in the screening interval of a biennial population-based screening programme. *J Med Screen*
39. Törnberg S, Kemetli L, Lynge E et al (2006)
Breast cancer incidence and mortality in the Nordic capitals, 1970-1998. Trends related to mammography screening programmes. *Acta Oncol.*
40. Hofvind S, Sørum R, Haldorsen T et al (2006)
Incidence of breast cancer before and after implementation of mammography screening *Tidsskr Nor Laegeforen.* Norwegian
41. Skaane P, Niklason L (2006)
Receiver operating characteristic analysis: a proper measurement for performance in breast cancer screening? *AJR Am J Roentgenol.* Author reply.
42. Hofvind S, Bjurstam N, Sørum R et al (2006)
Number and characteristics of breast cancer cases diagnosed in four periods in the screening interval of a biennial population-based screening programme. *J Med Screen.*
43. Hagen AI, Kvistad KA, Maehle L et al (2007)
Sensitivity of MRI versus conventional screening in the diagnosis of BRCA-associated breast cancer in a national prospective series. *Breast.*
44. Skaane P, Kshirsagar A, Stapleton S et al (2007)
Effect of computer-aided detection on independent double reading of paired screen-film and full-field digital screening mammograms. *AJR Am J Roentgenol.*
45. Hofvind S (2007)
Breast cancer screening--prevalence of disease in women who only respond after an invitation reminder. *J Med Screen.*
46. Geller B, Zapka J, Hofvind et al (2007)
Communicating with women about mammography. *J Cancer Educ.*
47. Hofvind S, Geller B, Vacek P et al (2007)
Using the European guidelines to evaluate the Norwegian Breast Cancer Screening Program. *Eur J Epidemiol.*
48. Skaane P, Kshirager A, Stapleton S (2007)
Effect of computer-aided detection on independent double reading of paired screen-film and full-field digital screening mammograms. *AJR Am J Roentgenol.*
49. Vigeland E, Klaasen H, Klingen TA, Hofvind P, Skaane P (2007)
Full-field digital mammography compared to screen film mammography in the prevalent round of a population-based screening programme: the Vestfold County Study. *Eur Radiol*
50. Skaane P, Hofvind S, Skjennald A (2007)
Randomized Trial Comparing Screen-Film Mammography and Full-Field Digital Mammography with Soft-Copy Reading in a Population-based Screening Program: Follow-up and Final Results of the Oslo-II Study. *Radiology*
51. Hofvind S, Sørum R, Thoresen S (2007)
Incidence and tumor characteristics of breast cancer diagnosed before and after implementation of a population-based screening-program. *Acta Oncologica*
52. Bremnes Y, Ursin G, Bjurstam N, Gram IT (2007)
Different measures of smoking exposure and mammographic density in postmenopausal Norwegian women: a cross-sectional study. *Breast Cancer Res.*
53. Bremnes Y, Ursin G, Bjurstam N, Rinaldi S, Kaaks R, Gram IT (2007)
Endogenous sex hormones, prolactin and mammographic density in postmenopausal Norwegian women. *Int J Cancer.*
54. Skaane P, Diekmann F, Balleyguier C et al (2008)
Observer variability in screen-film mammography versus full-field digital mammography with soft-copy reading. *Eur Radiol.*

55. Gram IT, Lund E (2008)
Breast cancer screening programme as setting for an adjunct research project: effect on programme attendance. *J Med Screen*.
56. Hofvind S, Vacek PM, Skelly J et al (2008)
Comparing screening mammography for early breast cancer detection in Vermont and Norway. *J Natl Cancer Inst*.
57. Østerlie W, Solbjør M, Skolbekken JA, Hofvind S et al (2008)
Challenges of informed choice in organised screening. *J Med Ethics*.
58. Kalager M (2008)
Unclear about overdiagnosis of breast cancer. *Ugeskr Laeger*
59. Sauer T, Karimzadeh M (2008)
Characteristic cytological features of histological grade one (G1) breast carcinomas in fine needle aspirates. *Cytopathology*.
60. Hofvind S, Geller B, Skaane P (2008)
Mammographic features and histopathological findings of interval breast cancers. *Acta Radiol*.
61. Zahl PH, Maehlen J, Welch HG (2008)
The natural history of invasive breast cancers detected by screening mammography. *Arch Intern Med*.
62. Skaane P (2009)
Studies comparing screen-film mammography and full-field digital mammography in breast cancer screening: updated review. *Acta Radiol*.
63. Weedon-Fekjaer H, Lindqvist BH, Vatten LJ, Aalen OO, Tretli S.(2008)
Estimating mean sojourn time and screening sensitivity using questionnaire data on time since previous screening. *J Med Screen*
64. Weedon-Fekjaer H, Lindqvist BH, Vatten LJ, Aalen OO, Tretli S (2008)
Breast cancer tumor growth estimated through mammography screening data. *Breast Cancer Res*
65. Kalager M, Bretthauer M (2009)
Spontaneous regression of invasive breast cancer: does this study answer the question? *Arch Intern Med*.
66. Kalager M, Haldorsen T, Bretthauer M et al (2009)
Improved breast cancer survival following introduction of an organized mammography screening program among both screened and unscreened women: a population-based cohort study. *Breast Cancer Res*
67. Gøtzsche PC, Jørgensen KJ, Maehlen J, Zahl (2009)
PH Estimation of lead time and overdiagnosis in breast cancer screening. *Br J Cancer*.
68. Hofvind S, Vee B, Sørnum R, Hauge M, Ertzaas AKO (2009). Quality assurance of mammograms in the Norwegian Breast Cancer Screening Program. *European Journal of Radiography*
69. Suhrke P, Zahl PH, Maehlen J (2009)
Declining breast cancer incidence and decreased HRT use. *Lancet*.
70. Stuedal A, Ma H, Bjørndal H, Ursin G (2009)
Postmenopausal hormone therapy with estradiol and norethisterone acetate and mammographic density: findings from a cross-sectional study among Norwegian women. *Climacteric*.
71. Kurz KD, Roy S, Mödder U, Skaane P, Saleh A (2009)
Typical atypical findings on dynamic MRI of the breast. *Eur J Radiol*.
72. Hofvind S, Geller BM, Rosenberg RD, Skaane P (2009)
Screening-detected breast cancers: discordant independent double reading in a population-based screening program. *Radiology*.
73. Hofvind S, Yankaskas BC, Bulliard JL, et al (2009)
Comparing interval breast cancer rates in Norway and North Carolina: results and challenges. *J Med Screen*.

74. Skaane P (2009)
Molecular imaging: a potential new tool for early detection and monitoring of targeted breast cancer therapy. *Acta Radiol.*
75. Kalager M, Kåresen R, Wist E (2009)
Survival after breast cancer--differences between Norwegian counties. *Tidsskr Nor Lægeforening*
76. Pedersen K, Landmark ID (2009)
Trial of a proposed protocol for constancy control of digital mammography systems. *Medical Physics*
77. Weedon-Fekjaer H, Sørnum R, Brenn MK (2009)
Hormone therapy use may explain recent results regarding tumor regression. *Arch Intern Med.*
78. Myklebust AM, Seierstad T, Strandén E, Lerdal A (2009)
Level of satisfaction during mammography screening in relation to discomfort, service provided, level of pain and breast compression. *European Journal of Radiography*
79. Weedon-Fekjær H, Tretli S, Aalen OO.(2010)
Estimating screening test sensitivity and tumour progression using tumour size and time since previous screening. *Stat Methods Med Res.*
80. Törnberg S, Kemetli L, Ascunce N, Hofvind S et al (2010)
A pooled analysis of interval cancer rates in six European countries. *Eur J Cancer Prev*
81. Aaroe J, Lindahl T, Dumeaux V et al (2010)
Gene expression profiling of peripheral blood cells for early detection of breast cancer. *Breast Cancer Res*
82. Møller H, Sandin F, Bray F, Klint A, Linklater KM, Purushotham A, Robinson D, Holmberg L. (2010)
Breast cancer survival in England, Norway and Sweden: A population-based comparison. *Breast cancer survival in England, Norway and Sweden: A population-based comparison. Int J Cancer.*
83. Opsahl EM, Westre B, Samset JH, Olafsson S, Michelsen K, Varhaug JE.(2010)
Breast cancer--diagnosis and treatment in a Alesund hospital. *Tidsskr Nor Lægeforen*
84. Sørnum R, Hofvind S, Skaane P, Haldorsen T. (2010)
Trends in incidence of ductal carcinoma in situ: The effect of a population-based screening programme. *The Breast.*
85. Haakensen VD, Biong M, Lingjærde OC, Holmen MM, Frantzen JO, Chen Y, Navjord D, Romundstad L, Lüders T, Bukholm IK, Solvang HK, Kristensen VN, Ursin G, Børresen-Dale AL, Helland A.(2010)
Expression levels of uridine 5'-diphospho-glucuronosyltransferase genes in breast tissue from healthy women are associated with mammographic density. *Breast Cancer Res.*
86. Kalager M, Zelen M, Langmark F, Adami HO (2010).
Effect of screening mammography on breast-cancer mortality in Norway. *New Eng J Med*
87. Juel IM, Skaane P, Hoff SR, Johannessen G, Hofvind S (2010)
Screen-film mammography versus full-field digital mammography in a population-based screening program: The Sogn and Fjordane study. *Acta Radiol.*
88. Dowling EC, Klabunde C, Patnick J, Ballard-Barbash R et al; International Cancer Screening Network (ICSN) (2010).
Breast and cervical cancer screening programme implementation in 16 countries. *J Med Screen*
89. Hoff SR, Samset JH, Abrahamsen AL, Vigeland E, Klepp O, Hofvind S.(2011).
Missed and true interval and screen-detected breast cancers in a population based screening program. *Acad Radiol*
90. Hauge IH, Pedersen K, Sanderud A, Hofvind S, Olerud HM. (2011).
PATIENT DOSES FROM SCREEN-FILM AND FULL-FIELD DIGITAL MAMMOGRAPHY IN A POPULATION-BASED SCREENING PROGRAMME. *Radiat Prot Dosimetry*
91. Hofvind S, Iversen BF, Eriksen L, Styr BM, Kjellevoid K, Kurz KD. (2011).
Mammographic morphology and distribution of calcifications in ductal carcinoma in situ diagnosed in organized screening. *Acta Radiol*

92. Skaane P. (2011). Nationwide mammography screening registers: the best way to go for mortality evaluation - but there is no free lunch. *Acta Radiol*
93. Falk RS, Hofvind S, Skaane P, Haldorsen T. (2011). Second events following ductal carcinoma in situ of the breast: a register-based cohort study. *Breast Cancer Res Treat.*
94. Hofvind S, Sakshaug S, Ursin G, Graff-Iversen S (2011). Breast cancer incidence trends in Norway - explained by hormone therapy or mammographic screening? *Int J Cancer*
95. Suhrke P, Mæhlen J, Schlichting E, Jørgensen KJ, Gøtzsche PC, Zahl PH. (2011). Effect of mammography screening on surgical treatment for breast cancer in Norway: comparative analysis of cancer registry data. *BMJ.*
96. Haakensen VD, Bjørro T, Lüders T, Riis M, Bukholm IK, Kristensen VN, Troester MA, Homen MM, Ursin G, Børresen-Dale AL, Helland Å. (2011). Serum estradiol levels associated with specific gene expression patterns in normal breast tissue and in breast carcinomas. *BMC Cancer.*
97. Lynge E, Braaten T, Njor SH, Olsen AH, Kumle M, Waaseth M, Lund E. (2011). Mammography activity in Norway 1983 to 2008. *Acta Oncol.*
98. Qureshi SA, Couto E, Hilsen M, Hofvind S, Wu AH, Ursin G. (2011). Mammographic density and intake of selected nutrients and vitamins in Norwegian women. *Nutr Cancer.*
99. Haakensen VD, Lingjaerde OC, Lüders T, Riis M, Prat A, Troester MA, Holmen MM, Frantzen JO, Romundstad L, Navjord D, Bukholm IK, Johannesen TB, Perou CM, Ursin G, Kristensen VN, Børresen-Dale AL, Helland A (2011). Gene expression profiles of breast biopsies from healthy women identify a group with claudin-low features. *BMC Med Genomics.*
100. Hafslund B, Espehaug B, Nortvedt MW. (2011). Effects of False-Positive Results in a Breast Screening Program on Anxiety, Depression and Health-Related Quality of Life. *Cancer Nurs.*
101. Kalager M. (2011). Regression of screening-detected breast cancer. *Lancet Oncol.*
102. Solbjør M, Forsmo S, Skolbekken JA, Sætnan AR. (2011). Experiences of recall after mammography screening--a qualitative study. *Health Care Women Int.*
103. Bock K, Borisch B, Cawson J, Damtjernhaug B, de Wolf C, Dean P, den Heeten A, Doyle G, Fox R, Frigerio A, Gilbert F, Hecht G, Heindel W, Heywang-Köbrunner SH, Holland R, Jones F, Lernevall A, Madai S, Mairs A, Muller J, Nisbet P, O'Doherty A, Patnick J, Perry N, Regitz-Jedermann L, Rickard M, Rodrigues V, Del Turco MR, Scharpantgen A, Schwartz W, Seradour B, Skaane P, Tabar L, Tornberg S, Ursin G, Van Limbergen E, Vandenbroucke A, Warren LJ, Warwick L, Yaffe M, Zappa M. (2011). Effect of population-based screening on breast cancer mortality. *Lancet.*
104. Skaane P. (2011). Controversies in mammography screening: let us not ignore science in this never-ending debate. *Acta Radiol.*
105. Hauge IH, Pedersen K, Sanderud A, Hofvind S, Olerud HM (2012). Patient doses from screen-film and full-film digital mammography in a population based screening-program. *Radiat Prot Dosimetry*
106. Weedon-Fekjaer H, Bakken K, Vatten LJ, Tretli S (2012). Understanding recent trends in incidence of invasive breast cancer in Norway: age-period-cohort analysis based on registry data on mammography screening and hormone treatment use. *BMJ*
107. Zahl PH, Mæhlen J (2012). Overdiagnosis of breast cancer after 14 years of mammography screening. *Tidsskr Nor Laegeforen*
108. Couto E, Qureshi SA, Hofvind S, Hilsen M, Aase H, Skaane P, Vatten L, Ursin G. (2012). Hormone therapy use and mammographic density in postmenopausal Norwegian women. *Breast Cancer Res Treat.*
109. Qureshi SA, Couto E, Hofvind S, Wu AH, Ursin G (2012). Alcohol intake and mammographic density in postmenopausal Norwegian women. *Breast Cancer Res Treat.*
110. Skaane P, Kshirsagar A, Hofvind S, Jahr G, Castellino RA (2012). Mammography screening using independent double reading with consensus: Is there a potential benefit for computer-aided detection? *Acta Radiol.*
111. Kalager M, Adami HO, Bretthauer M, Tamimi RM (2012). Overdiagnosis of invasive breast cancer due to mammography screening: results from the Norwegian screening program. *Ann Intern Med.*

112. Olsen AH, Lynge E, Njor SH, Kumle M, Waaseth M, Braaten T, Lund E (2012). Breast cancer mortality in Norway after the introduction of mammography screening. *Int J Cancer*.
113. Hofvind S, Skaane P. Stage Distribution of Breast Cancer Diagnosed Before and After Implementation of Population-Based Mammographic Screening (2012). *Rofo*. 2012 May;184(5):437-42. Epub 2012 Mar 17
114. Norum J, Hofvind S, Nieder C, Schnell EA, Broderstad AR. Mammographic screening in Sami speaking municipalities and a control group. Are early outcome measures influenced by ethnicity? *Int J Circumpolar Health*. 2012 Apr 16;71:1-6. doi: 10.3402/ijch.v71i0.18205.
115. Hoff SR, Abrahamsen AL, Samset JH, Vigeland E, Klepp O, Hofvind S. Breast Cancer: Missed Interval and Screening-detected Cancer at Full-Field Digital Mammography and Screen-Film Mammography-- Results from a Retrospective Review. *Radiology*. 2012 Aug;264(2):378-86.
116. Hofvind S, Lee CI, Elmore JG. Stage-specific breast cancer incidence rates among participants and non-participants of a population-based mammographic screening program. *Breast Cancer Res Treat*. 2012 Aug;135(1):291-9.
117. Solbjør M, Skolbekken JA, Sætnan AR, Hagen AI, Forsmo S. Mammography screening and trust: The case of interval breast cancer. *Soc Sci Med*. 2012 Nov;75(10):1746-52. doi: 10.1016/j.socscimed.2012.07.029. Epub 2012 Aug.
118. Hafslund B, Espehaug B, Nortvedt MW. Effects of false-positive results in a breast screening program on anxiety, depression and health-related quality of life. *Cancer Nurs*. 2012 Sep;35(5):E26-34.
119. Hafslund B, Espehaug B, Nortvedt MW. Health-related quality of life, anxiety and depression related to mammography screening in Norway. *J Clin Nurs*. 2012 Sep 1. doi: 10.1111/j.1365-2702.2012.04244.x. [Epub ahead of print]
120. Falk RS, Hofvind S, Skaane P. Overdiagnosis of Invasive Breast Cancer due to Mammography Screening. *Ann Intern Med*. 2012 Aug 7;157(3):219; author reply 221-2. doi: 10.7326/0003-4819-157-3-201208070-00021.
121. Hofvind S, Geller BM, Skelly J, Vacek PM. Sensitivity and specificity of mammographic screening as practiced in Vermont and Norway. *Br J Radiol*. 2012 Sep 19.
122. Hansen BT, Nygård M, Falk RS, Hofvind S. Breast cancer and ductal carcinoma in situ among women with prior squamous or glandular precancer in the cervix: a register-based study. *Br J Cancer*. 2012 Oct 23;107(9):1451-3. doi: 10.1038/bjc.2012.438. Epub 2012 Sep 25.
123. Schou Bredal I, Kåresen R, Skaane P, Engelstad KS, Ekeberg O. Recall mammography and psychological distress. *Eur J Cancer*. 2012 Sep 27. doi:p11: S0959-8049(12)00693-4. 10.1016/j.ejca.2012.09.001.
124. Paci E; EUROSCREEN Working Group. Summary of the evidence of breast cancer service screening outcomes in Europe and first estimate of the benefit and harm balance sheet. *J Med Screen*. 2012;19 Suppl 1:5-13.
125. Broeders M, Moss S, Nyström L, Njor S, Jonsson H, Paap E, Massat N, Duffy S, Lynge E, Paci E; EUROSCREEN Working Group. The impact of mammographic screening on breast cancer mortality in Europe: a review of observational studies. *J Med Screen*. 2012;19 Suppl 1:14-25.
126. Moss SM, Nyström L, Jonsson H, Paci E, Lynge E, Njor S, Broeders M; Euroscreen Working Group. The impact of mammographic screening on breast cancer mortality in Europe: a review of trend studies. *J Med Screen*. 2012;19 Suppl 1:26-32.
127. Njor S, Nyström L, Moss S, Paci E, Broeders M, Segnan N, Lynge E; Euroscreen Working Group. Breast cancer mortality in mammographic screening in Europe: a review of incidence-based mortality studies. *J Med Screen*. 2012;19 Suppl 1:33-41.
128. Puliti D, Duffy SW, Miccinesi G, de Koning H, Lynge E, Zappa M, Paci E; EUROSCREEN Working Group. Overdiagnosis in mammographic screening for breast cancer in Europe: a literature review. *J Med Screen*. 2012;19 Suppl 1:42-56.
129. Hofvind S, Ponti A, Patnick J, Ascunce N, Njor S, Broeders M, Giordano L, Frigerio A, Törnberg S; EUNICE Project and Euroscreen Working Groups. False-positive results in mammographic

- screening for breast cancer in Europe: a literature review and survey of service screening programmes. *J Med Screen*. 2012;19 Suppl 1:57-66.
130. Giordano L, Cogo C, Patnick J, Paci E; Euroscreen Working Group. Communicating the balance sheet in breast cancer screening. *J Med Screen*. 2012;19 Suppl 1:67-71.
 131. Giordano L, von Karsa L, Tomatis M, Majek O, de Wolf C, Lancucki L, Hofvind S, Euroscreen Working Group. Mammographic screening programmes in Europe: organization, coverage and participation. *J Med Screen*. 2012;19 Suppl 1:72-82.
 132. Ellingjord-Dale M, Lee E, Couto E, Ozhand A, Qureshi SA, Hofvind S, Van Den Berg DJ, Akslen LA, Grotmol T, Ursin G. Polymorphisms in hormone metabolism and growth factor genes and mammographic density in Norwegian postmenopausal hormone therapy users and non-users. *Breast Cancer Res*. 2012 Oct 27;14(5):R135.
 133. Solbjør M, Skolbekken JA, Sætnan AR, Hagen AI, Forsmo S. Could screening participation bias symptom interpretation? An interview study on women's interpretations of and responses to cancer symptoms between mammography screening rounds. *BMJ Open*. 2012 Nov 12;2(6). doi:pil: e001508. 10.1136/bmjopen-2012-001508. Print 2012.
 134. Kalager M, Tamimi RM, Bretthauer M, Adami HO. Prognosis in women with interval breast cancer: population based observational cohort study. *BMJ*. 2012 Nov 16;345:e7536. doi: 10.1136/bmj.e7536.
 135. Hauge IH, Olerud HM. UNCERTAINTIES INVOLVED IN THE ESTIMATION OF MEAN GLANDULAR DOSE FOR WOMEN IN THE NORWEGIAN BREAST CANCER SCREENING PROGRAM (NBCSP). *Radiat Prot Dosimetry*. 2012 Nov 27.
 136. Sauer T, Suci V. The role of preoperative axillary lymph node fine needle aspiration in locoregional staging of breast cancer. *Ann Pathol*. 2012 Dec;32(6):e24-8. doi: 10.1016/j.annpat.2012.09.229. Epub 2012 Nov 22.
 137. Qureshi SA, Ellingjord-Dale M, Hofvind S, Wu AH, Ursin G. Physical activity and mammographic density in a cohort of postmenopausal Norwegian women; a cross-sectional study. *Springerplus*. 2012 Dec;1(1):75. Epub 2012 Dec 21.
 138. Skaane P, Bandos AI, Gullien R, Eben EB, Ekseth U, Haakenaasen U, Izadi M, Jepsen IN, Jahr G, Krager M, Niklason LT, Hofvind S, Gur D. Comparison of Digital Mammography Alone and Digital Mammography Plus Tomosynthesis in a Population-based Screening Program. *Radiology*. 2013 Jan 7. [Epub ahead of print].
 139. Falk RS, Hofvind S, Skaane P, Haldorsen T. Overdiagnosis among women attending a population-based mammography screening program. *Int J Cancer*. 2013 Jan 25. doi: 10.1002/ijc.28052. [Epub ahead of print].
 140. Hoff SR, Klepp O, Hofvind S. Asymptomatic breast cancer in non-participants of the national screening-programme in Norway: a confounding factor in evaluation? *J Med Screen*. 2013 Feb 6. [Epub ahead of print].
 141. Houssami N, Skaane P. Overview of the evidence on digital breast tomosynthesis in breast cancer detection. *Breast*. 2013 Feb 16. pii: S0960-9776(13)00019-2. doi: 10.1016/j.breast.2013.01.017. [Epub ahead of print].
 142. Skaane P, Bandos AI, Gullien R, Eben EB, Ekseth U, Haakenaasen U, Izadi M, Jepsen IN, Jahr G, Krager M, Hofvind S. Prospective trial comparing full-field digital mammography (FFDM) versus combined FFDM and tomosynthesis in a population-based screening programme using independent double reading with arbitration. *Eur Radiol*. 2013 Apr 4. [Epub ahead of print].
 143. Hofvind S. Organised mammographic screening--more benefits than harms. *Tidsskr Nor Laegeforen*. 2013 Mar 19;133(6):619-20. doi: 10.4045/tidsskr.12.0911.
 144. Klinge TA¹, Chen Y, Suhrke P, Stefansson IM, Gundersen MD, Akslen LA. Expression of thyroid transcription factor-1 is associated with a basal-like phenotype in breast carcinomas. *Diagn Pathol*. 2013 May 15;8:80. doi: 10.1186/1746-1596-8-80.
 145. Hofvind S, Ursin G, Tretli S, Sebuødegård S, Møller B. Breast cancer mortality in participants of the Norwegian Breast Cancer Screening Program. *Cancer*. 2013 May 29. doi: 10.1002/cncr.28174. [Epub ahead of print].

146. Ozhand A, Lee E, Wu AH, Ellingjord-Dale M, Akslen LA, McKean-Cowdin R, Ursin G. Variation in inflammatory cytokine/growth-factor genes and mammographic density in premenopausal women aged 50-55. *PLoS One*. 2013 Jun 7;8(6):e65313. doi: 10.1371/journal.pone.0065313. Print 2013.
147. Hofvind S, Schlichting E, Ursin G, Sebuødegård S, Kåresen R. Breast cancer surgery in Norway 1986 – 2009. *Tidsskr Nor Laegeforen*. 2013 Aug 20;133(15):1582-6. doi: 10.4045/tidsskr.12.0840. Norwegian.
148. Roman M, Hubbard RA, Sebuodegard S, Miglioretti DL, Castells X, Hofvind S. The cumulative risk of false-positive results in the Norwegian Breast Cancer Screening Program: Updated results. *Cancer*. 2013 Aug 20. doi: 10.1002/cncr.28320. [Epub ahead of print].
149. Zahl PH, Jørgensen KJ, Gøtzsche PC. Overestimated lead times in cancer screening has led to substantial underestimation of overdiagnosis. *Br J Cancer*. 2013 Aug 20. doi: 10.1038/bjc.2013.427. [Epub ahead of print].
150. Lynge E, Ponti A, James T, Májek O, von Euler-Chelpin M, Anttila A, Fitzpatrick P, Frigerio A, Kawai M, Scharpantgen A, Broeders M, Hofvind S, Vidal C, Ederra M, Salas D, Bulliard JL, Tomatis M, Kerlikowske K, Taplin S; the ICSN DCIS Working group. Variation in detection of ductal carcinoma in situ during screening mammography: A survey within the International Cancer Screening Network. *Eur J Cancer*. 2014 Jan;50(1):185-92. doi: 10.1016/j.ejca.2013.08.013. Epub 2013 Sep 13. PMID 24041876.
151. Zahl PH. The information about mammography screening is not neutral. *Tidsskr Nor Laegeforen*. 2013 Aug 20;133(15):1557-8. doi: 10.4045/tidsskr.13.0551.
152. Hofvind S, Ursin G. Informasjon om mammografiscreening.[In Process Citation]. *Tidsskr Nor Laegeforen*. 2013 Oct 15;133(19):2024-5. doi: 10.4045/tidsskr.13.1238. Norwegian.
153. S R Hoff. Mammografiscreening – på tide å flytte fokus.[In Process Citation]. *Tidsskr Nor Laegeforen*. 2013 Oct 15;133(19):2025. doi: 10.4045/tidsskr.13.1237.
154. Hauge IH, Pedersen K, Olerud HM, Hole EO, Hofvind S. The risk of radiation-induced breast cancers due to biennial mammographic screening in women aged 50-69 years is minimal. *Acta Radiol*. 2013 Dec 5. [Epub ahead of print]
155. Lund E, Mode N, Waaseth M, Thalabard JC. Overdiagnosis of breast cancer in the Norwegian Breast Cancer Screening Program estimated by the Norwegian Women and Cancer cohort study. *BMC Cancer*. 2013 Dec 30;13:614. doi: 10.1186/1471-2407-13-614.
156. Qureshi SA, Lund AC, Veierød MB, Carlsen MH, Blomhoff R, Andersen LF, Ursin G. Food items contributing most to variation in antioxidant intake; a cross-sectional study among Norwegian women. *BMC Public Health*. 2014 Jan 16;14(1):45. doi: 10.1186/1471-2458-14-45.
157. Duffy SW, Michalopoulos D, Sebuødegård S, Hofvind S. Trends in aggregate cancer incidence rates in relation to screening and possible overdiagnosis: A world of caution. *J Med Screen*. 2014 Jan 21. [Epub ahead of print]
158. Lousdal ML¹, Kristiansen IS, Møller B, Støvring H. Trends in breast cancer stage distribution before, during and after introduction of a screening programme in Norway. *Eur J Public Health*. 2014 Mar 4.
159. Zahl PH¹, Jørgensen KJ, Gøtzsche PC. Lead-Time Models Should Not Be Used to Estimate Overdiagnosis in Cancer Screening. *J Gen Intern Med*. 2014 Mar 4.
160. Kalager M¹, Løberg M, Bretthauer M, Adami HO. Comparative analysis of breast cancer mortality following mammography screening in Denmark and Norway. *Ann Oncol*. 2014 Mar 24.
161. Skaane P¹, Gullien R², Eben EB², Sandhaug M³, Schulz-Wendtland R⁴, Stoeblen F⁵. Interpretation of automated breast ultrasound (ABUS) with and without knowledge of mammography: a reader performance study. *Acta Radiol*. 2014 Mar 28. pii: 0284185114528835. [Epub ahead of print].
162. Hofvind S¹, Skaane P, Elmore JG, Sebuødegård S, Hoff SR, Lee CI. Mammographic Performance in a Population-based Screening Program: Before, during, and after the Transition from Screen-Film to Full-Field Digital Mammography. *Radiology*. 2014 Apr 1:131502.

163. Skaane P, Bandos AI, Eben EB, Jepsen IN, Krager M, Haakenaasen U, Ekseth U, Izadi M, Hofvind S, Gullien R. Two-View Digital Breast Tomosynthesis Screening with Synthetically Reconstructed Projection Images: Comparison with Digital Breast Tomosynthesis with Full-Field Digital Mammographic Images. *Radiology*. 2014 Jan 24;131391. *Radiology*. 2014 Jun;271(3):655-63. doi: 10.1148/radiol.13131391. Epub 2014 Jan 24.
164. Roman M, Skaane P, Hofvind S. The cumulative risk of false-positive screening results across screening centres in the Norwegian Breast Cancer Screening Program. *Eur J Radiol*. 2014 Sep;83(9):1639-44. doi: 10.1016/j.ejrad.2014.05.038. Epub 2014 Jun 5.
165. Weedon-Fekjær H, Romundstad PR, Vatten LJ. Modern mammography screening and breast cancer mortality: population study. *BMJ*. 2014 Jun 17;348:g3701. doi: 10.1136/bmj.g3701.
166. Falk RS. Why are results of organized mammography screening so difficult to interpret? *Tidsskr Nor Laegeforen*. 2014 Jun 17;134(11):1124-6. doi: 10.4045/tidsskr.13.1655. eCollection 2014 Jun 17. English, Norwegian. No abstract available.
167. Paci E, Broeders M, Hofvind S, Puliti D, Duffy SW; EUROSCREEN Working Group. European breast cancer service screening outcomes: a first balance sheet of the benefits and harms. *Cancer Epidemiol Biomarkers Prev*. 2014 Jul;23(7):1159-63. doi: 10.1158/1055-9965.EPI-13-0320.
168. Ellingjord-Dale M, Grotmol T, Lee E, Van Den Berg DJ, Hofvind S, Couto E, Sovio U, Dos Santos Silva I, Ursin G. Breast cancer susceptibility variants and mammographic density phenotypes in Norwegian postmenopausal women. *Cancer Epidemiol Biomarkers Prev*. 2014 Sep;23(9):1752-63. doi: 10.1158/1055-9965.EPI-13-1212. Epub 2014 Jul 7.
169. Ponti A, Lynge E, James T, Májek O, von Euler-Chelpin M, Anttila A, Fitzpatrick P, Mano MP, Kawai M, Scharpantgen A, Fracheboud J, Hofvind S, Vidal C, Ascunce N, Salas D, Bulliard JL, Segnan N, Kerlikowske K, Taplin S; ICSN DCIS Working group. International variation in management of screen-detected ductal carcinoma in situ of the breast. *Eur J Cancer*. 2014 Oct;50(15):2695-704. doi: 10.1016/j.ejca.2014.07.019. Epub 2014 Aug 19 .
170. Skaane P. Dose hysteria and concern about radiation exposure should not prevent women from undergoing life-saving mammography screening. *Acta Radiol*. 2014 Dec;55(10):1155-6. doi: 10.1177/0284185114530547.
171. Solbjør M¹, Skolbekken JA, Østerlie W, Forsmo S. Women's Experiences With Mammography Screening Through 6 Years of Participation-A Longitudinal Qualitative Study. *Health Care Women Int*. 2014 Dec 15:1-20 [Epub ahead of print].
172. Chen Y, Klingen TA, Wik E, Aas H, Vigeland E, Liestøl K, Garred Ø, Mæhlen J, Akslen LA, Lømo J. Breast cancer stromal elastosis is associated with mammography screening detection, low Ki67 expression and favourable prognosis in a population-based study. *Diagn Pathol*. 2014 Dec 19;9(1):230. [Epub ahead of print].
173. Hartmann-Johnsen OJ¹, Kåresen R, Schlichting E, Nygård JF. Survival is Better After Breast Conserving Therapy than Mastectomy for Early Stage Breast Cancer: A Registry-Based Follow-up Study of Norwegian Women Primary Operated Between 1998 and 2008. *Ann Surg Oncol*. 2015 Mar 6. [Epub ahead of print].
174. Løberg M, Lousdal ML, Bretthauer M, Kalager M. Benefits and harms of mammography screening. *Breast Cancer Res*. 2015 May 1;17(1):63.
175. Ellingjord-Dale M, Dos-Santos-Silva I, Grotmol T, Kaur Sakhi A, Hofvind S, Qureshi S, Skov Markussen M, Couto E, Vos L, Ursin G. Vitamin d intake, month the mammogram was taken and mammographic density in norwegian women aged 50-69. *PLoS One*. 2015 May 4;10(5):e0123754. doi: 10.1371/journal.pone.0123754. eCollection 2015.
176. Zahl PH¹, Mæhlen J² Bias in Observational Studies of the Association between Menopausal Hormone Therapy and Breast Cancer. *PLoS One*. 2015 May 4;10(5):e0124076. doi: 10.1371/journal.pone.0124076. eCollection 2015.
177. Suhrke P^{1,2}, Zahl PH³ Breast cancer incidence and menopausal hormone therapy in Norway from 2004 to 2009: a register-based cohort study. *Cancer Med*. 2015 May 20. doi: 10.1002/cam4.474. [Epub ahead of print].

178. Hofvind S¹, Holen Å², Aas T³, Roman M⁴, Sebuødegård S², Akslen LA⁵. Women treated with breast conserving surgery do better than those with mastectomy independent of detection mode, prognostic and predictive tumor characteristics. *Eur J Surg Oncol*. 2015 Oct;41(10):1417-22. doi: 10.1016/j.ejso.2015.07.002. Epub 2015 Jul 17.
179. Moger TA¹, Bjørnelv GM, Aas E. Expected 10-year treatment cost of breast cancer detected within and outside a public screening program in Norway. *Eur J Health Econ*. 2015 Aug 4. [Epub ahead of print].
180. M.Boyce, R.Gullien, D.Parashar, K.Taylor. Comparing the use and interpretation of PGMI scoring to assess the technical quality of screening mammograms in the UK and Norway. *Radiography*, 07/17/2015. DOI: <http://dx.doi.org/10.1016/j.radi.2015.05.006>.
181. Román M, Sakshaug S, Graff-Iversen S, Vangen S, Weiderpass E, Ursin G, Hofvind S. Postmenopausal hormone therapy and the risk of breast cancer in Norway. *Int J Cancer*. 2015 Aug 20. doi: 10.1002/ijc.29810. [Epub ahead of print]
182. Moshina N, Ursin G, Hoff SR, Akslen LA, Roman M, Sebuødegård S, Hofvind S. Mammographic density and histopathologic characteristics of screen-detected tumors in the Norwegian Breast Cancer Screening Program. *Acta Radiol Open*. 2015 Sep 17;4(9):2058460115604340. doi: 10.1177/2058460115604340. eCollection 2015 sep.
183. Domingo L, Hofvind S, Hubbard RA, Román M, Benkeser D, Sala M, Castells X. Cross-national comparison of screening mammography accuracy measures in U.S., Norway, and Spain. *Eur Radiol*. 2015 Nov 11. [Epub ahead of print]
184. Hofvind S, Holen Å, Román M, Sebuødegård S, Puig-Vives M, Akslen L. Mode of detection: an independent prognostic factor for women with breast cancer. *J Med Screen*. 2015 Nov 17. pii: 0969141315604006. [Epub ahead of print]
185. Moshina N, Ursin G, Roman M, Sebuødegård S, Hofvind S. Positive predictive values by mammographic density and screening mode in the Norwegian Breast Cancer Screening Program. *Eur J Radiol*. 2016 Jan;85(1):248-54. doi: 10.1016/j.ejrad.2015.11.030. Epub 2015 Nov 25
186. Markussen MS¹, Veierød MB¹, Kristiansen AL¹, Ursin G¹, Andersen LF¹. Dietary patterns of women aged 50-69 years and associations with nutrient intake, sociodemographic factors and key risk factors for non-communicable diseases. *Public Health Nutr*. 2016 Jan 19:1-9. [Epub ahead of print]
187. Østerås BH¹, Martinsen AC², Brandal SH³, Chaudhry KN³, Eben E³, Haakenaasen U³, Falk RS⁴, Skaane P⁵. Classification of fatty and dense breast parenchyma: comparison of automatic volumetric density measurement and radiologists' classification and their inter-observer variation. *Acta Radiol*. 2016 Jan 20. pii: 0284185115626469. [Epub ahead of print]
188. Østerås BH¹, Martinsen AC², Brandal SH³, Chaudhry KN³, Eben E³, Haakenaasen U³, Falk RS⁴, Skaane P⁵. BI-RADS Density Classification From Areometric and Volumetric Automatic Breast Density Measurements. *Acad Radiol*. 2016 Feb 1. pii: S1076-6332(16)00020-9. doi: 10.1016/j.acra.2015.12.016. [Epub ahead of print]
189. Lousdal ML¹, Kristiansen IS², Møller B³, Støvring H¹. Effect of organised mammography screening on stage-specific incidence in Norway: population study. *Br J Cancer*. 2016 Feb 2. doi: 10.1038/bjc.2016.8. [Epub ahead of print]
190. Hofvind S¹, Bennett RL², Brisson J³, Lee W⁴, Pelletier E⁵, Flugelman A⁶, Geller B⁷. Audit feedback on reading performance of screening mammograms: An international comparison. *J Med Screen*. 2016 Feb 17. pii: 0969141315610790. [Epub ahead of print]
191. Román M^{1,2}, Castells X^{3,4}, Hofvind S^{1,5}, von Euler-Chelpin M⁶. Risk of breast cancer after false-positive results in mammographic screening. *Cancer Med*. 2016 Feb 25. doi: 10.1002/cam4.646. [Epub ahead of print]
192. Michalopoulos D, Duffy SW. Estimation of overdiagnosis using short-term trends and lead time estimates uncontaminated by overdiagnosed cases: Results from the Norwegian Breast Screening Programme. *J Med Screen*. 2016 Mar 2. pii: 0969141315623980. [Epub ahead of print].

193. Hofvind S, Román M, Sebuødegård S, Falk RS. Balancing the benefits and detriments among women targeted by the Norwegian Breast Cancer Screening Program. *J Med Screen*. 2016 Mar 2. pii: 0969141315625088. [Epub ahead of print]
194. Falk RS, Hofvind S. Over-diagnosis in mammographic screening due to competing risk of death. *Cancer Epidemiol Biomarkers Prev*. 2016 May;25(5):759-65. doi: 10.1158/1055-9965.EPI-15-0819. Epub 2016 Mar 14.
195. Houssami N, Lång K, Bernardi D, Tagliafico A, Zackrisson S, Skaane P. Digital breast tomosynthesis (3D-mammography) screening: A pictorial review of screen-detected cancers and false recalls attributed to tomosynthesis in prospective screening trials. *Breast*. 2016 Apr;26:119-34. doi: 10.1016/j.breast.2016.01.007. Epub 2016 Feb 18. Review.
196. Weedon-Fekjær H, Romundstad PR, Vatten LJ. Modern mammography screening and breast cancer mortality: population study. *BMJ*. 2014 Jun 17;348:g3701. doi: 10.1136/bmj.g3701.
197. Haukaas TH, Euceda LR, Giskeødegård GF, Lamichhane S, Krohn M, Jernström S, Aure MR, Lingjærde OC, Schlichting E, Garred Ø, Due EU, Mills GB, Sahlberg KK, Børresen-Dale AL, Bathen TF; Oslo Breast Cancer Consortium (OSBREAC). Metabolic clusters of breast cancer in relation to gene- and protein expression subtypes. *Cancer Metab*. 2016 Jun 27;4:12. doi: 10.1186/s40170-016-0152-x.
198. Lesurf R, Aure MR, Mørk HH, Vitelli V; Oslo Breast Cancer Research Consortium (OSBREAC)., Lundgren S, Børresen-Dale AL, Kristensen V, Wärnberg F, Hallett M, Sørli T. Molecular Features of Subtype-Specific Progression from Ductal Carcinoma In Situ to Invasive Breast Cancer. *Cell Rep*. 2016 Jul 26;16(4):1166-79. doi: 10.1016/j.celrep.2016.06.051.
199. Markussen MS, Veierød MB, Ursin G, Andersen LF. The effect of under-reporting of energy intake on dietary patterns and on the associations between dietary patterns and self-reported chronic disease in women aged 50-69 years. *Br J Nutr*. 2016 Aug;116(3):547-58. doi: 10.1017/S000711451600218X.
200. Waade GG, Highnam R, Hauge IH, McEntee MF, Hofvind S, Denton E, Kelly J, Sarwar JJ, Hogg P. Impact of errors in recorded compressed breast thickness measurements on volumetric density classification using volpara v1.5.0 software. *Med Phys*. 2016 Jun;43(6):2870. doi: 10.1118/1.4948503.
201. Sas-Chen A, Aure MR, Leibovich L, Carvalho S, Euka Y, Körner C, Polycarpou-Schwarz M, Lavi S, Nevo N, Kuznetsov Y, Yuan J, Azuaje F; Oslo Breast Cancer Research Consortium (OSBREAC). LIMT is a novel metastasis inhibiting lncRNA suppressed by EGF and downregulated in aggressive breast cancer. *EMBO Mol Med*. 2016 Sep 1;8(9):1052-64. doi: 10.15252/emmm.201606198.
202. Deandrea S, Molina-Barceló A, Uluturk A, Moreno J, Neamtii L, Peiró-Pérez R, Saz-Parkinson Z, Lopez-Alcalde J, Lerda D, Salas D. Presence, characteristics and equity of access to breast cancer screening programmes in 27 European countries in 2010 and 2014. Results from an international survey. *Prev Med*. 2016 Oct;91:250-263. doi: 10.1016/j.ypmed.2016.08.021.
203. Klingen TA, Chen Y, Stefansson IM, Knutsvik G, Collett K, Abrahamsen AL, Aase H, Aas H, Aas T, Wik E, Akslen LA. Tumour cell invasion into blood vessels is significantly related to breast cancer subtypes and decreased survival. *J Clin Pathol*. 2016 Sep 9. pii: jclinpath-2016-203861. doi: 10.1136/jclinpath-2016-203861. [Epub ahead of print].
204. Sebuødegård S, Sagstad S, Hofvind S. Attendance in the Norwegian Breast Cancer Screening Programme. *Tidsskr Nor Laegeforen*. 2016 Sep 27;136(17):1448-51. doi: 10.4045/tidsskr.15.1013. Norwegian.
205. Jørgensen KJ, Kalager M, Barratt A, Baines C, Zahl PH, Brodersen J, Harris RP. Overview of guidelines on breast screening: Why recommendations differ and what to do about it. *Breast*. 2016 Oct 4. pii: S0960-9776(16)30138-2. doi: 10.1016/j.breast.2016.08.002. [Epub ahead of print].
206. van Luijt PA, Heijnsdijk EA, van Ravesteyn NT, Hofvind S, de Koning HJ. Breast cancer incidence trends in Norway and estimates of overdiagnosis. *J Med Screen*. 2016 Oct 17. pii: 0969141316668379. [Epub ahead of print].

207. Sardanelli F, Aase HS, Álvarez M, Azavedo E, et al. Position paper on screening for breast cancer by the European Society of Breast Imaging (EUSOBI) and 30 national breast radiology bodies from Austria, Belgium, Bosnia and Herzegovina, Bulgaria, Croatia, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Israel, Lithuania, Moldova, The Netherlands, Norway, Poland, Portugal, Romania, Serbia, Slovakia, Spain, Sweden, Switzerland and Turkey. *Eur Radiol.* 2016 Nov 2. [Epub ahead of print].
208. van Luijt PA, Heijnsdijk EA, de Koning HJ. Cost-effectiveness of the Norwegian breast cancer screening program. *Int J Cancer.* 2016 Nov 11. doi: 10.1002/ijc.30513. [Epub ahead of print].
209. Román M, Graff-Iversen S, Weiderpass E, Vangen S, Sakshaug S, Hofvind S, Ursin G. Postmenopausal Hormone Therapy and Breast Cancer Prognostic Characteristics: A Linkage between Nationwide Registries. *Cancer Epidemiol Biomarkers Prev.* 2016 Nov;25(11):1464-1473.
210. Hofvind S, Román M, Sebuødegård S, Falk RS. Balancing the benefits and detriments among women targeted by the Norwegian Breast Cancer Screening Program. *J Med Screen.* 2016 Dec;23(4):203-209.
211. Vikestad KG, Hafskjold L, Kjelle E, Sebuødegård S, Hofvind S. Radiographers' opinions on radiography research in Norway - A national survey. *Radiography (Lond).* 2017 May;23(2):135-140. doi: 10.1016/j.radi.2016.12.006. Epub 2017 Jan 17.
212. Egeland EV, Boye K, Park D, Synnestvedt M, Sauer T; Oslo Breast Cancer Consortium (OSBREAC)., Naume B, Borgen E, Mælandsmo GM. Prognostic significance of S100A4-expression and subcellular localization in early-stage breast cancer. *Breast Cancer Res Treat.* 2017 Feb;162(1):127-137. doi: 10.1007/s10549-016-4096-1. Epub 2017 Jan 5.
213. Ellingjord-Dale M, Vos L, Tretli S, Hofvind S, Dos-Santos-Silva I, Ursin G. Parity, hormones and breast cancer subtypes - results from a large nested case-control study in a national screening program. *Breast Cancer Res.* 2017 Jan 23;19(1):10. doi: 10.1186/s13058-016-0798-x.
214. Waade GG, Hofvind S, Thompson JD, Highnam R, Hogg P. Development of a phantom to test fully automated breast density software - A work in progress. *Radiography (Lond).* 2017 Feb;23(1):e14-e19. doi: 10.1016/j.radi.2016.09.003. Epub 2016 Oct 3.
215. Moshina N, Sebuødegård S, Hofvind S. Is breast compression associated with breast cancer detection and other early performance measures in a population-based breast cancer screening program? *Breast Cancer Res Treat.* 2017 Jun;163(3):605-613. doi: 10.1007/s10549-017-4214-8. Epub 2017 Mar 29.
216. Aure MR, Vitelli V, Jernström S, Kumar S, Krohn M, Due EU, Haukaas TH, Leivonen SK, Vollan HK, Lüders T, Rødland E, Vaske CJ, Zhao W, Møller EK, Nord S, Giskeødegård GF, Bathen TF, Caldas C, Tramm T, Alsner J, Overgaard J, Geisler J, Bukholm IR, Naume B, Schlichting E, Sauer T, Mills GB, Kåresen R, Mælandsmo GM, Lingjærde OC, Frigessi A, Kristensen VN, Børresen-Dale AL, Sahlberg KK; OSBREAC. Integrative clustering reveals a novel split in the luminal A subtype of breast cancer with impact on outcome. *Breast Cancer Res.* 2017 Mar 29;19(1):44. doi: 10.1186/s13058-017-0812-y.
217. Waade GG, Sanderud A, Hofvind S. Compression force and radiation dose in the Norwegian Breast Cancer Screening Program. *Eur J Radiol.* 2017 Mar;88:41-46. doi: 10.1016/j.ejrad.2016.12.025. Epub 2016 Dec 31.
218. Waade GG, Moshina N, Sebuødegård S, Hogg P, Hofvind S. Compression forces used in the Norwegian Breast Cancer Screening Program. *Br J Radiol.* 2017 Mar;90(1071):20160770. doi: 10.1259/bjr.20160770. Epub 2017 Feb 17.
219. Moshina N, Roman M, Sebuødegård S, Waade GG, Ursin G, Hofvind S. Comparison of subjective and fully automated methods for measuring mammographic density. *Acta Radiol.* 2017 Jan 1:284185117712540. doi: 10.1177/0284185117712540. [Epub ahead of print]